Clinical Trials
16 trialsNCT04648189 2023-10-19
Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
The Netherlands Cancer Institute
Phase 2 Withdrawn
NCT00954876 2022-10-20
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Translational Genomics Research Institute
Phase 2 Withdrawn
NCT01020864 2020-11-02
CECAVI
Odense University Hospital
Phase 2 Withdrawn
NCT03688230 2020-03-18
AMELION
SFJ Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00934518 2019-02-12
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
Milton S. Hershey Medical Center
Phase 2 Withdrawn
NCT00577109 2018-07-31
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 2 Withdrawn
NCT00571740 2016-07-06
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Withdrawn
NCT02014831 2016-02-25
PENILANE
Centre Leon Berard
Phase 2 Withdrawn
NCT00768131 2015-10-28
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
Eli Lilly and Company
Phase 2 Withdrawn
NCT00881114 2015-03-27
PGx-SELECT
Georgetown University
Phase 2 Withdrawn
NCT00005591 2013-12-13
Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT00636298 2013-11-19
Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy
Emory University
Phase 2 Withdrawn
NCT01427205 2013-04-05
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00766220 2013-01-03
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00998101 2012-03-06
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00725400 2011-07-20
Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma
American Scitech International
Phase 2 Withdrawn